FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs

Submitted by admin on March 5, 2023 - 3:08pm
Source: 
BioPharma Dive
News Tags: 
Merck
AstraZeneca
Lynparza
FDA
PARP inhibitors
Headline: 
FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs
snippet: 

The Food and Drug Administration will convene an expert panel in April to review use Merck & Co. and AstraZeneca’s Lynparza in patients newly diagnosed with advanced prostate cancer, the companies said Thursday.

Do Not Allow Advertisers to Use My Personal information